Global Micafungin Sodium for Injection Market and Forecast 2020-2026

                                          
Micafungin (trade name Mycamine) is an echinocandin antifungal drug used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.

In 2013, Japan was the largest consumption place, with a consumption market share nearly 35.40%. In 2017, North America is the largest consumption place with the consumption market share of 28.98%.

Market Analysis and Insights: Global Micafungin Sodium for Injection Market


The research report studies the Micafungin Sodium for Injection market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.

The global Micafungin Sodium for Injection market size is projected to reach US$ 301.7 million by 2026, from US$ 349 million in 2020, at a CAGR of -2.4% during 2021-2026.

Global Micafungin Sodium for Injection Scope and Segment

The global Micafungin Sodium for Injection market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Micafungin Sodium for Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.

by Type, the market is primarily split into

 	
50 mg Single-use Vial
 	
100 mg Single-use Vial

by Application, this report covers the following segments

 	
Candidemia
 	
Respiratory Mycosis
 	
Gastrointestinal Mycosis

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

The Micafungin Sodium for Injection key players in this market include:

 	
Astellas